Latest "Mifepristone Cushing Syndrome" News Stories

13:07 EDT 3rd September 2015 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,100+

Extremely Relevant

Bilateral Adrenal Incidentalomas Linked to Cushing Syndrome

Subclinical Cushing syndrome is more likely among patients with bilateral adrenal incidentalomas than among those with unilateral lesions, but surgery may not be the best approach to management. Medscape Medical News

Relevant

OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018

Recently added to the BioPortfolio report store, OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 is a new report from GlobalData published on 2015-01-08. This 194-page report is available in PDF from $4650. OpportunityAnalyzer: Cushing’s Syndrome - Opportunity Analysis and Forecasts to 2018 Summary GlobalData estimates that the 2013 sales for the Cushing...

Quotient Clinical Delivers First In-human Program for Corcept Therapeutics

Focus is on treatment of Cushing’s syndrome and certain cancers

Corcept Therapeutics (CORT) - ASCO Abstract on Mifepristone to treat Breast Cancer

On the evening of May 13, 2015, a press release was published about Corcept’s current Phase I/II trial of mifepristone

Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing's Syndrome at the 27th Annual American Association of Clinical Endocrinologists

MENLO PARK, CA -- (Marketwired) -- 05/14/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that four posters about mifepristone will be presented at the 24th annual American Association of Clinical Endocrino...

Corcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing's Syndrome at the 97th Annual Endocrine Society Meeting

MENLO PARK, CA -- (Marketwired) -- 03/05/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that a variety of posters about Korlym® (mifepristone) will be presented at the 97th annual Endocrine Society Meeti...

Corcept (CORT) - Thots on Korlym's Cancer Trials - ASCO Abstract

On the evening of May 13, 2015, a press release was published about Corcept’s current Phase I/II trial of mifepristone

Rethinking Corcept Therapeutics (CORT), Part III of IV: Introduction to the New Pipeline

Rethinking Corcept: The Upcoming Pipeline It’s still early in Corcept’s portfolio development but important phase II trials are ongoing with independent investigators. Results should arrive over the next 15 to 18 months and will enable Corcept to select for its current basket of development targets. We think this includes:

Corcept Therapeutics (CORT) Releases Q4 2014 Financials and Update

On March 4, 2015, Corcept Therapeutics (CORT) released its quarterly financial results for Q4 2014 and provided a clinical update. In the earlier release, Corcept provided limited data and sales guidance for 2015.The effect of increasing sales on the financial metrics is immediately apparent.  While net sales was only $26.6M for 2014, it made a significant difference. The net loss was $3.9M f...

Corcept Therapeutics to Announce Second Quarter Financial Results and Corporate Update and Host Conference Call

MENLO PARK, CA -- (Marketwired) -- 07/29/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United S...

Rethinking Corcept Therapeutics (CORT), Part III of IV: Introduction to the Future Pipeline

Rethinking Corcept: The Upcoming Pipeline Important phase II trials are ongoing with independent investigators. These results should arrive over the next 15 to 18 months and enable Corcept creates a new basket of development targets. We think this includes:

Mifepristone: Interim Phase I/II data

Corcept Therapeutics - $17.2M From Exercise of Outstanding Warrants + Additional Thoughts

On Wednesday April 1, 2015, Corcept Therapeutics announced gross receipt of $17.2M from the exercise of warrants. This gives Corcept much needed breathing room. With the additional cash, we guesstimate that Corcept currently has about $37M in cash.The table below summarizes all the warrants outstanding for Corcept at the end of 2014. As of December 31, 2014

Rethinking Corcept Therapeutics (CORT), Part I of III: Thinking about Cancer

The New BioWatch Team recently visited CEO Joe Belanoff at the Corcept HQ in Menlo Park, CA. We wanted to follow-up on the recent Q1 2015 conference call as well as extend our own thinking regarding Corcept.We have separated this into three parts: Part I is focused on

Quotient delivers breakthrough first-in-human program for Corcept

Quotient Clinical announced the successful completion of an Enabled-First-in-Human® program for U.S. biotech company Corcept Therapeutics. The program focused on a next generation selective glucocorticoid receptor antagonist (CORT125134) in developm...

Now Available! Lynch Syndrome: Get the Facts

Ask the Experts Series: A Family Affair: When Cancer Runs in the Family Lynch Syndrome: Get the Facts about this Hereditary Cancer Syndrome In this informative web chat, genetic counselor, Megan Myers, discusses what Lynch syndrome is, how you can ...

Corcept Therapeutics - $17.2M From Exercise of Outstanding Warrants

On Wednesday April 1, 2015, Corcept Therapeutics announced gross receipt of $17.2M from the exercise of warrants. This gives Corcept much needed breathing room. We guesstimate that Corcept currently has about $37M in cash.The table below summarizes all the warrants outstanding for Corcept at the end of 2014. As of December 31, 2014

Celebrating the Biomedical Achievements on World Down Syndrome Day

Guest Post by Sara Hart Weir, MS, President, National Down Syndrome Society On March 21, we celebrate the 10th Annual World Down Syndrome Day.  It was established and eventually recognized by the United Nations as a means to raise awareness and mo...

New Tool for Down Syndrome Research

Researchers, clinicians, and other professionals with an interest in Down syndrome can now access deidentified data from DS-Connect: The Down Syndrome Registry, where people in the Down syndrome community voluntarily and securely store personal healt...

Non-FDA-Approved Abortion Regimen Shows Efficacy

Dr Peter Kovacs summarizes the results of a study in which patients were given 200 mg mifepristone followed by 800 mcg misoprostol. Medscape Ob/Gyn

Rethinking Corcept Therapeutics (CORT), Part II of III: Thinking about Metabolic Syndrome

Corcept Therapeutics is a strange duck. Last June it failed a Phase III trial and had to shut down its only late stage program. It was at $4.42 per share at its peak before the failed Phase III results. On June 12, 2015, CORT flew with a higher valuation and share price $6.66 per share).The company has

REVISED & FINISHED - Rethinking Corcept Therapeutics (CORT), Part I of III: Thinking about Cancer

The New BioWatch Team recently visited CEO Joe Belanoff at the Corcept HQ in Menlo Park, CA. We wanted to follow-up on the recent Q1 2015 conference call as well as extend our own thinking regarding Corcept.We have separated this into three parts: Part I is focused on

Rethinking Corcept Therapeutics (CORT), Part I of IV: Thinking about Cancer

The New BioWatch Team recently visited CEO Joe Belanoff at the Corcept HQ in Menlo Park, CA. We wanted to follow-up on the recent Q1 2015 conference call as well as extend our own thinking regarding Corcept.We have separated this into three parts: Part I is focused on

Rethinking Corcept Therapeutics (CORT), Part II of IV: Thinking about Metabolic Syndrome

Corcept Therapeutics is a strange duck. Last June it failed a Phase III trial and had to shut down its only late stage program. It was at $4.42 per share at its peak before the failed Phase III results. On June 12, 2015, CORT flew with a higher valuation and share price (closed at $6.66 per share).The company has

Corcept Therapeutics (CORT) Q1 2015 Update

On May 7, 2015, Corcept Therapeutics (CORT) reported its quarterly financial results for Q1 2015 and hosted a conference call. The ongoing Corcept story arcs towards its cancer-related milestones.     Corcept reported a moderate increase in Korlym sales     Korlym moves to efficacy portion of Phase I/II trial to treat GR+ triple negative breast cancer &...



Advertisement
 
Advertisement
 

News Quicklinks